RESEARCH ARTICLE

Kidney Dysfunction in Adult Offspring Exposed In Utero to Type 1 Diabetes Is Associated with Alterations in Genome-Wide DNA Methylation

Jean-François Gautier¹,²,³*, Raphaël Porcher⁴, Charbel Abi Khalil⁵, Naima Bellili-Munoz³, Lila Sabrina Fetita¹, Florence Travert⁵,⁶, Simeon-Pierre Choukem¹, Jean-Pierre Rivelin³,⁷, Samy Hadjadj⁸, Étienne Larger⁹, Philippe Boudou¹⁰, Bertrand Blondeau³, Ronan Roussel⁵,¹¹, Pascal Ferre³, Eric Ravussin¹², François Rouzet¹³, Michel Marre⁵,⁶,¹¹

¹ Department of Diabetes and Endocrinology, Assistance Publique–Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France, ² Clinical Investigation Center, INSERM-CIC9504, Saint-Louis University Hospital, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France, ³ INSERM UMRS 1138, Cordeliers Research Center, University Pierre et Marie Curie Paris-6, Paris, France, ⁴ Department of Biostatistics and Medical Computing, Saint-Louis University Hospital, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France, ⁵ Department of Diabetes, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, DHU FIRE, University Paris-Diderot Paris-7, Paris, France, ⁶ Clinical Investigation Center, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France, ⁷ Department of Diabetes and Endocrinology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France, ⁸ Department of Endocrinology and Diabetes, Centre Hospitalier Universitaire, Poitiers, France, ⁹ Department of Diabetes, Hôtel-Dieu Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France, ¹⁰ Unit of Transfer in Molecular Oncology and Hormonology, Saint-Louis University Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France, ¹¹ INSERM U695, University Paris-Diderot Paris-7, Paris, France, ¹² Penington Biomedical Research Center, Baton Rouge, LA, United States of America, ¹³ Department of Nuclear Medicine, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France

* jean-francois.gautier@lrb.aphp.fr

Abstract

Background
Fetal exposure to hyperglycemia impacts negatively kidney development and function.

Objective
Our objective was to determine whether fetal exposure to moderate hyperglycemia is associated with epigenetic alterations in DNA methylation in peripheral blood cells and whether those alterations are related to impaired kidney function in adult offspring.

Design
Twenty nine adult, non-diabetic offspring of mothers with type 1 diabetes (T1D) (case group) were matched with 28 offspring of T1D fathers (control group) for the study of their leukocyte genome-wide DNA methylation profile (27,578 CpG sites, Human Methylation 27 BeadChip, Illumina Infinium). In a subset of 19 cases and 18 controls, we assessed renal vascular
development by measuring Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) at baseline and during vasodilatation produced by amino acid infusion.

**Results**

Globally, DNA was under-methylated in cases vs. controls. Among the 87 CpG sites differently methylated, 74 sites were less methylated and 13 sites more methylated in cases vs. controls. None of these CpG sites were located on a gene known to be directly involved in kidney development and/or function. However, the gene encoding DNA methyltransferase 1 (DNMT1)—a key enzyme involved in gene expression during early development—was under-methylated in cases. The average methylation of the 74 under-methylated sites differently correlated with GFR in cases and controls.

**Conclusion**

Alterations in methylation profile imprinted by the hyperglycemic milieu of T1D mothers during fetal development may impact kidney function in adult offspring. The involved pathways seem to be a nonspecific imprinting process rather than specific to kidney development or function.

**Introduction**

Fetal programming defines a phenomenon by which an alteration of intrauterine environment predisposes to the development of disorders later in life. Evidence came from epidemiological data showing that tobacco exposure, caloric restriction, and severe hyperglycemia during pregnancy as well as severe pregnancy-related hypertension are all determinants of low birth weight [1], which is associated with higher prevalence of metabolic and cardiovascular disorders at adult age (review in [2]). Hyperglycemia during pregnancy independently of birth weight is also associated with higher risks of cardio-metabolic disease later in life [3–7].

A reduced number of nephrons has been associated with primary hypertension and renal and cardiovascular risks in humans [8, 9]. The number of nephrons is determined at birth in humans [10] and is correlated to birth weight [11], supporting a role of intrauterine environment on kidney function at adult age.

We previously investigated adult individuals born from type 1 diabetic mothers as a model of fetal exposure to maternal hyperglycemia, taking those born from type 1 diabetic fathers as controls [12, 13]. Hence the genetic background in relation to type 1 diabetes is equivalent in exposed subjects and controls. Data obtained in offspring of type 2 diabetic mothers (4) can be obscured by the backgrounds of essential hypertension, or other components of the insulin resistance syndrome so frequently associated with type 2 diabetes. Then, we were able to investigate the impact of hyperglycemia per se on kidney function. We found that fetal exposure to maternal type 1 diabetes is associated at adult age with a reduced functional reserve by measuring glomerular filtration rate and effective renal plasma flow [13], a surrogate of functional nephron numbers [8]. This finding was consistent with studies in a rat model in which moderate hyperglycemia during pregnancy was associated with a decreased number of nephrons in offspring [14], which favored the development of hypertension at adulthood [15].

The molecular mechanisms involved in the development of impaired renal function in offspring of diabetic mothers are yet to be unravelled. Alterations of the expressions of IGFs and their receptors in fetal kidney were reported in rats exposed in utero to maternal hyperglycemia.
Because of its impact on kidney development, abnormal angiogenesis may be a plausible mechanism \[17, 18\]. In a classical model of angiogenesis, we observed that high glucose levels induce a defect in angiogenesis by increasing apoptosis and reducing proliferation of endothelial cells without affecting the expression of several growth factors involved in angiogenesis \[19\].

If adverse fetal environment irreversibly programs adult disease, then DNA epigenetic modifications may be involved. DNA methylations and histone modifications are two key epigenetic changes in chromatin structure that directly influence gene transcription, expression, and cellular functions and consequently, tissue development \[20\]. DNA methylation, the most studied transcriptional epigenetic modification, is characterized by the covalent addition of a methyl group on a cytosine base by DNA methyl transferases in CpG dinucleotides (CpG sites). When CpG methylation occurs in promoter regions of genes, transcription is usually decreased. It may be thus involved in gene silencing, genomic imprinting, and chromosomal stability \[21\] and consequently be a potential mechanism linking hyperglycemia exposure during fetal development and renal dysfunction in adulthood \[20\]. DNA methylation may vary depending on cell type so that DNA methylation profile may differ from one organ to another, except if DNA methylation changes occurred very early in the fetal development.

In the present study we used a microarray technique to seek potential alterations in genome-wide DNA methylation in blood cells from adult subjects who had been exposed in utero to maternal type 1 diabetes. We also investigated whether these alterations are associated with renal dysfunction.

**Materials and Methods**

**Subjects**

Participants were direct offspring of type 1 diabetic subjects attending specialized clinics in 6 French hospitals: Hôpital Saint-Louis, Hôpital Bichat–Claude Bernard, Hôtel-Dieu, Institut Montsouris all in Paris, Centre Hospitalier Universitaire in Poitiers, and Centre Hospitalier Sud Francilien in Corbeil, Essonne.

Cases and controls were selected to have one parent with type 1 diabetes (as defined by the American Diabetes Association) for at least two years before offspring conception. Eligibility was possible if the other parent was not diabetic at time of study. All mothers did not smoke during pregnancy. Offspring were men or women at least 18 years of age not pregnant at time of investigation for women and without diabetes as checked with an oral glucose tolerance test. They were free of immune marker of type 1 diabetes (anti-islet antibodies, antibodies against GAD, IA2, and IA2 beta, and anti-insulin antibodies). Chronic drug intake, acute infection, any chronic disease, and personal or family history of kidney disease, other than possible diabetic nephropathy in their diabetic parents were excluded. Cases were offspring of type 1 diabetic mothers, and controls offspring of type 1 diabetic fathers.

The current study is part of a research program designed to investigate the physiological consequences of fetal exposure to maternal type 1 diabetes at adult age in 62 offspring recruited between 2006 and 2009. Genomic DNA isolated from whole blood samples was available for CpG sites methylation assay in 57 offspring, 29 cases and 28 controls. Among them, 19 cases and 18 controls were studied for baseline and amino acid-stimulated Glomerular Filtration Rate (GFR), and Effective Renal Plasma Flow (ERPF), using a 51Cr EDTA plus 123I-hippurate primed constant infusion technique as previously described \[13\].

**Ethics statement**

The study was approved by the local Ethical Committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Paris Saint-Louis; AOR 04032) and each participant gave a written informed consent to participate.
Genome-wide DNA methylation analysis

Methylation of 27,578 CpG sites at 14,475 consensus coding sequencing sites was performed using the Illumina Human Methylation27 BeadChip system at the Integragen SA at Evry, France, as previously described [22, 23]. Briefly, 4 ml of bisulfite converted DNA was amplified overnight at 37°C. The amplified DNA product was fragmented by an endpoint enzymatic process. Fragmented DNA was precipitated, resuspended, and applied to an Infinium Human Methylation27 BeadChip and hybridized overnight. During hybridization, the amplified and fragmented DNA samples anneal to specific oligomers that are covalently linked to over 27,000 different bead types. Each bead type corresponds to the nucleotide identity and thus the methylation status at a bisulfite-converted cytosine in a specific CpG site. The bead chips were then subjected to a single-base extension reaction using the hybridized DNA as a template incorporating fluorescently labelled nucleotides of two different colors, each corresponding to the cytosine (methylated) or uracil (unmethylated) identity of the bisulfite-converted nucleotide. The fluorescently stained chip was imaged by the Illumina BeadArray Reader. Illumina’s Genome Studio program was used to analyze BeadArray data to assign site-specific DNA methylation β-values to each CpG site. The β-value defined the proportion of methylation for each subject at each CpG site which was computed by first subtracting the background signal intensity of negative controls from both the methylated and unmethylated signals and then taking the ratio of the methylated signal intensity to the sum of both methylated and unmethylated signals. Thus, the β-value is a continuous variable ranging between 0 and 1.

Data analyses

Quality control. The detection p-value as provided by Illumina is obtained by comparing the signal generated by each CpG site to negative controls. CpG sites with missing β-values or detection p-value > 0.01 for more than 5 patients were eliminated from the analysis. This strategy led to discard 1509 CpG sites (5.5%), thus leaving 26,069 CpG sites among 57 subjects for the analysis.

Fig 1 illustrates the methylation profile of 4 randomly selected subjects (panel A), showing that individuals have a peak of low methylated CpG sites, a smaller peak of high methylated sites, and a small proportion of moderately methylated sites. As an example, Panel B depicts the distributions of methylations (β-value) at selected CpG sites for the 57 subjects.

Determination of differentially methylated CpG sites between cases and controls. After initial quality control as described above, a sample of 57 subjects (29 cases and 28 controls) was tested for association between fetal exposure status and gene-specific methylation. In this analysis, the logit-transformed β-value of each CpG site was compared between cases and controls using t-tests. Then, p-values were obtained from B = 100 permutations of the t-statistics as described in Storey & Tibshirani [24, 25]. More precisely, the exposure status of subjects were randomly permuted B = 100 times, thus leading to 100 samples where no association between methylation at each CpG site and exposure is expected (because exposure was mixed across subjects at random). For each CpG site j, the new artificial “case” and “control” groups were compared, leading to t-statistics $t_{ij}^{\text{perm}}$, $b = 1, \ldots, B$. For a given CpG site i, $i = 1, \ldots, n_{\text{CpG}}$, $n_{\text{CpG}}$ (= 26,069), the p-value $p_i$ was calculated as

$$p_i = \frac{\sum_{b=1}^{B} \# \{ j : |t_{ij}^{\text{perm}}| \geq |t_{ij}|, j = 1, \ldots, n_{\text{CpG}} \}}{n_{\text{CpG}} \times B}.$$

CpG sites were considered as differentially methylated if they achieved a p-value below the pre-specified arbitrary threshold of 0.005. Cut-off p-values commonly used in similar DNA
methylation chip studies are set between 0.05 and 0.005 [23, 26]. Average methylation of up-methylated and down-methylated sites in cases was then computed and its association with renal parameters analyzed using multiple regression models with the renal parameter as dependent variable and the group (case or control), the average methylation and their interaction as independent variables.

Analyses were performed using the R statistical programming software (the R foundation for Statistical Computing, Vienna, Austria)

Identification of biological processes. Further analysis of the differentially methylated genes was conducted for potential biological significance using an automated method of literature interrogation, the Acumenta Literature Lab: it identifies and ranks associations existing in the literature between gene sets, such as those derived from microarray experiments, and curated sets of key terms such as pathway names, medical subject heading [27]. First, the software was questioned with known pathways or genes involved in kidney development and function such as IGF2, angiogenesis, renin angiotensin system or in renal disease risk such as APOL1 and MYH9 [28]. In a second step, we ran the software without a priori.

Methylation specific PCR. In order to validate DNA methylation changes detected by the genome-wide analysis from Illumina Chip, we performed methylation specific PCR (Epitect, Qiagen) for some most differentially methylated genes accordingly to the manufacturer instructions.

Results

Characteristics of parents and offspring are shown in Table 1. They were similar in the 2 groups except for the prevalence of late prematurity (born between 34 and 37 weeks of pregnancy) which was higher in the offspring of diabetic mothers (cases) than in offspring of diabetic fathers (controls). There was no preterm delivery less than 34 weeks of pregnancy and only one
case was born at 34 weeks. In order to seek differences in methylation profile between case and controls, we looked at the distribution of t-statistics at each CpG sites. We found that the observed distribution differed from its expectation in case of no difference in DNA methylation between case and controls, and was shifted in favor of higher methylation in controls (Fig 2).

As shown in Table 2, 87 CpG sites were differentially methylated between cases and controls. Among them, 74 were down-methylated and 13 sites were up-methylated in cases vs controls.

Interrogation of the Acumerta Literature Lab did not find methylation differences in known genes and pathways involved in kidney development and function between cases and controls. Using the software with no a priori, “Methylation pathway” was identified as the only pathway strongly (p = 0.0014) associated with down-methylated sites in cases. This was due to

Table 1. Characteristics of parents and offspring.

|                                      | Controls  | Cases     | p       |
|--------------------------------------|-----------|-----------|---------|
|                                      | (n = 28)  | (n = 29)  |         |
| Diabetic parent characteristics      |           |           |         |
| Sex, men/women                       | 28/0      | 0/29      |         |
| Current age, y                        | 56.7 (6.0)| 54.2 (6.6)| 0.14    |
| Age at diabetes onset, y             | 17.8 (8.5)| 15.5 (8.0)| 0.31    |
| Age at offspring birth, y            | 31.2 (4.8)| 27.9 (3.7)| 0.006   |
| Current Body mass index, kg/m²       | 25.5 (3.9)| 25.2 (4.1)| 0.81    |
| Nephropathy, no. (%)                 | 5 (19)    | 4 (14)    | >0.99   |
| Retinopathy, no. (%)                 | 24 (86)   | 20 (71)   | 0.33    |
| Macroangiopathy, no. (%)             | 6 (21)    | 5 (19)    | >0.99   |
| Birth data                           |           |           |         |
| Preterm delivery, no. (%)            | 0 (0)     | 10 (36)   | 0.003   |
| Birthweight, g                       | 3354 (474)| 3282 (661)| 0.66    |
| Offspring clinical characteristics    |           |           |         |
| Female gender, no. (%)               | 14 (50)   | 16 (55)   | 0.79    |
| Age, y                               | 25.6 (5.0)| 25.9 (6.2)| 0.85    |
| Body mass index, kg/m²               | 22.8 (2.8)| 23.2 (3.2)| 0.63    |
| Systolic blood pressure, mm Hg       | 122 (13)  | 123 (14)  | 0.85    |
| Diastolic blood pressure, mm Hg      | 67 (10)   | 69 (9)    | 0.52    |
| Body fat, %                          | 24.6 (8.0)| 26.3 (8.7)| 0.46    |
| Men                                  | 19.0 (6.1)| 19.5 (5.9)| 0.86    |
| Women                                | 30.1 (5.4)| 31.8 (6.3)| 0.47    |
| Waist circumference, cm              | 80 (9)    | 77 (9)    | 0.28    |
| Men                                  | 84 (8)    | 82 (11)   | 0.73    |
| Women                                | 77 (8)    | 74 (6)    | 0.43    |
| Offspring biological characteristics  |           |           |         |
| Serum creatinine, μmol/L             | 75 (11)   | 74 (14)   | 0.78    |
| Uricemia, μmol/L                     | 297 (86)  | 284 (72)  | 0.55    |
| Total cholesterol, mmol/L            | 4.5 (0.9) | 4.9 (1.0) | 0.093   |
| Triglycerides, mmol/L                | 0.95 (0.43)| 0.98 (0.39)| 0.79    |
| LDL cholesterol, mmol/L              | 2.6 (0.7) | 3 (1.1)   | 0.16    |
| HDL cholesterol, mmol/L              | 1.5 (0.3) | 1.7 (0.6) | 0.14    |

Mean (SD) otherwise stated.

doi:10.1371/journal.pone.0134654.t001
the DNA (cytosine-5-) methyltransferase 1 (DNMT1) gene which was less methylated (site cg15043801) in cases (Fig 3).

To confirm the Illumina Chip analysis, we performed DNA methylation specific PCR (Epi-pect, Qiagen) for 7 genes less methylated in offspring of diabetic mothers (DNMT1, TMBIM1, SOCS6, COL21A1, CCNA1, SURF5, GPR172A). We found that global methylation was lower in offspring of diabetic mothers: 0.005 (0.024–0.001) [median (75%Q–25%Q)] vs 0.013 (0.055–0.002) in offspring of diabetic fathers (p = 0.004).

We then studied possible relationships between the level of methylation in the differentially methylated sites between the 2 groups and kidney function parameters. We found an opposite correlation between the average level of methylation of the 74 sites less methylated in cases and Glomerular Filtration Rate in basal state (cases: r = 0.27 (95%CI:-0.22;0.66); controls: -0.44 (-0.75;0.03); p = 0.03 for interaction) and in response to amino acid infusion (cases: 0.10 (-0.38;0.54); controls: -0.47 (-0.77;-0.01); p = 0.06 for interaction). Although non-significant, a similar pattern of correlation was observed between the average level of methylation of the DNMT1 gene and Glomerular Filtration Rate (basal and stimulated). No correlation was found with other kidney parameters.

**Discussion**

Our results suggest that in utero exposure to hyperglycemia is associated with alterations in genome-wide DNA methylation profile. These alterations were related to kidney dysfunction in adults. We did not identify any differential methylation on genes currently known for their function in kidney development. One explanation could be that DNA methylation varies depending on cell type and we do not have evidences that DNA methylation profile in the kidney is similar to what is observed in peripheral leukocytes, except if DNA methylation changes occurred in the very early fetal development. Interestingly, one of the strongest observed
Table 2. Details on the 87 differentially methylated sites ranked by p-value. Direction (+) indicates higher methylation in cases and (-) in controls.

| SYMBOL | Gene name | Index | p-value | Direction |
|--------|-----------|-------|---------|-----------|
| FCN1   | ficolin 1 precursor | 17386 | 1.07E-05 | -         |
| ERMAP  | erythroblast membrane-associated protein | 17353 | 6.14E-05 | +         |
| MUC5B  | mucin 5; subtype B; tracheobronchial | 22377 | 0.00016 | -         |
| CYP4F3 | cytochrome P450; family 4; subfamily F; polypeptide 3 | 16455 | 0.00020 | -         |
| TMBIM1 | PP1201 protein | 25876 | 0.00023 | -         |
| SURF5  | surfet 5 isoform a | 19999 | 0.00024 | -         |
| DNMT1  | DNA (cytosine-5-)-methyltransferase 1 | 15041 | 0.00037 | -         |
| PROM2  | prominin 2 | 20721 | 0.00041 | -         |
| ORC5L  | origin recognition complex subunit 5 isoform 1 | 18297 | 0.00044 | -         |
| C7orf26| hypothetical protein LOC79034 | 27440 | 0.00057 | -         |
| FGF21  | fibroblast growth factor 21 precursor | 16223 | 0.00081 | -         |
| FBXO2  | F-box only protein 2 | 1430 | 0.00096 | -         |
| SOCS6  | suppressor of cytokine signaling 6 | 1541 | 0.0011 | -         |
| FLJ20186 | differentially expressed in FDCP 8 isoform 1 | 25192 | 0.0011 | +         |
| KCNO1  | potassium voltage-gated channel; KQT-like subfamily; member 1 isoform 1 | 16826 | 0.0011 | -         |
| TLL3   | tubulin tyrosine ligase-like family; member 3 isoform 2 | 3393 | 0.0011 | -         |
| CD209  | CD209 antigen | 1639 | 0.0011 | -         |
| GNAS   | guanine nucleotide binding protein; alpha stimulating activity polypeptide 1 isoform a | 7256 | 0.0011 | +         |
| C15orf2| hypothetical protein LOC23742 | 27330 | 0.0012 | +         |
| MYR8   | myosin heavy chain Myr 8 | 18936 | 0.0012 | -         |
| COL21A1| alpha 1 type XXI collagen precursor | 5188 | 0.0013 | -         |
| ABHD14A| abhydrolase domain containing 14A | 4514 | 0.0014 | -         |
| GNAT1  | guanine nucleotide binding protein; alpha transducing activity polypeptide 1 | 6788 | 0.0015 | -         |
| CCNA1  | cyclin A1 | 16506 | 0.0015 | -         |
| SCGB1A1| secretoglobin; family 1A; member 1 (uteroglobin) | 9424 | 0.0016 | -         |
| GPR172A| G protein-coupled receptor 172A | 16693 | 0.0019 | -         |
| CD40   | CD40 antigen isoform 1 precursor | 21586 | 0.0020 | -         |
| CD40   | CD40 antigen isoform 1 precursor | 25236 | 0.0020 | -         |
| TMC4   | transmembrane channel-like 4 | 25713 | 0.0020 | -         |
| MGMT   | O-6-methylguanine-DNA methyltransferase | 2946 | 0.0021 | -         |
| KCNB1  | potassium voltage-gated channel; Shab-related subfamily; member 1 | 14740 | 0.0021 | -         |
| NR5A1  | nuclear receptor subfamily 5; group A; member 1 | 724 | 0.0021 | -         |
| NMUR1  | neuromedin U receptor 1 | 18260 | 0.0021 | -         |
| COG2   | component of oligomeric golgi complex 2 | 17060 | 0.0022 | +         |
| C1orf22| hypothetical protein LOC80267 | 19913 | 0.0022 | -         |
| GTF3A  | general transcription factor IIIA | 24750 | 0.0022 | -         |
| ANXA9  | annexin A9 | 20401 | 0.0022 | -         |
| CTS1   | cathepsin L preproprotein | 11068 | 0.0023 | -         |
| CASKIN2| cask-interacting protein 2 | 4171 | 0.0023 | -         |
| DNAI1  | dynein; axonemal; intermediate polypeptide 1 | 8523 | 0.0024 | -         |
| CPNE6  | copine 6 | 1566 | 0.0024 | -         |
| SCAP   | SREBP cleavage-activating protein | 26572 | 0.0024 | +         |
| TPCN2  | two pore segment channel 2 | 22462 | 0.0024 | -         |
| PGAM2  | phosphoglycerate mutase 2 (muscle) | 26033 | 0.0025 | -         |
| BMP1R1A| bone morphogenetic protein receptor; type IA precursor | 6812 | 0.0025 | -         |
| APOB   | apolipoprotein B precursor | 5340 | 0.0026 | -         |
| USP4   | ubiquitin specific protease; proto-oncogene isoform a | 18877 | 0.0027 | -         |

(Continued)
Table 2. (Continued)

| SYMBOL | Gene name                                          | Index | p-value | Direction |
|--------|----------------------------------------------------|-------|---------|-----------|
| DKK2   | dickkopf homolog 2 precursor                       | 1409  | 0.0027  | -         |
| FLJ42486 | hypothetical protein LOC388021                      | 116   | 0.0027  | +         |
| FLJ32569 | hypothetical protein LOC148811                      | 14129 | 0.0027  | -         |
| FBXO17  | F-box protein FBG4 isoform 2                        | 8782  | 0.0027  | -         |
| CCDC28B | coiled-coil domain containing 28B                   | 13649 | 0.0027  | -         |
| PDE7B   | phosphodiesterase 7B                                | 2673  | 0.0028  | -         |
| PSENEN  | presenilin enhancer 2                               | 7811  | 0.0029  | -         |
| DEFA4   | defensin; alpha 4 preproprotein                     | 19296 | 0.0029  | -         |
| FLJ36046 | hypothetical protein LOC164592                     | 22234 | 0.0030  | -         |
| ITGA8   | integrin; alpha 8                                   | 13427 | 0.0030  | -         |
| C1orf42 | chromosome 1 open reading frame 42                  | 11694 | 0.0033  | -         |
| LRRC15  | leucine rich repeat containing 15                   | 26814 | 0.0033  | -         |
| MAGI2   | membrane associated guanylase kinase; WW and PDZ domain containing 2 | 20484 | 0.0033  | -         |
| SLC7A7  | solute carrier family 7 (cationic amino acid transporter; y+ system); member 7 | 19863 | 0.0034  | -         |
| WDR41   | WD repeat domain 41                                 | 2049  | 0.0034  | -         |
| HOXA2   | homeobox A2                                         | 9788  | 0.0035  | -         |
| BANF1   | barrier to autointegration factor 1                 | 21392 | 0.0037  | -         |
| LSM1    | Lsm1 protein                                       | 14732 | 0.0037  | +         |
| WFDC12  | WAP four-disulfide core domain 12 precursor         | 20441 | 0.0037  | -         |
| LITAF   | LPS-induced TNF-alpha factor                        | 8221  | 0.0037  | -         |
| SURF6   | surfet 6                                           | 18726 | 0.0037  | -         |
| PEG10   | paternally expressed 10                            | 6933  | 0.0038  | +         |
| FLJ30707 | hypothetical protein LOC220108                     | 3010  | 0.0038  | -         |
| PRLH    | prolactin releasing hormone                         | 11315 | 0.0039  | -         |
| MRPL18  | mitochondrial ribosomal protein L18                | 10544 | 0.0039  | -         |
| C20orf141 | hypothetical protein LOC128653                   | 1274  | 0.0040  | -         |
| PRPF31  | pre-mRNA processing factor 31 homolog             | 13591 | 0.0040  | +         |
| C6orf192 | hypothetical protein LOC116843                    | 13501 | 0.0040  | +         |
| ESPN    | Espin                                              | 12998 | 0.0041  | -         |
| CX36    | connexin-36                                        | 21020 | 0.0041  | -         |
| CGB     | chorionic gonadotropin beta 3 subunit precursor    | 554   | 0.0042  | -         |
| EPB41L4B | erythrocyte membrane protein band 4.1 like 4B isoform 2 | 19624 | 0.0042  | -         |
| HLA-DRA | major histocompatibility complex; class II; DR alpha precursor | 25745 | 0.0044  | -         |
| APOC2   | apolipoprotein C-II precursor                       | 27369 | 0.0044  | -         |
| MGC9850 | hypothetical protein MGC9850                       | 2325  | 0.0045  | -         |
| SIAHP1  | fuse-binding protein-interacting repressor isoform b | 18163 | 0.0045  | -         |
| LOC51315 | hypothetical protein LOC51315                     | 8253  | 0.0047  | +         |
| FAM26C  | hypothetical protein LOC255022                     | 9095  | 0.0048  | -         |
| PEPD    | Xaa-Pro dipeptidase                                | 9333  | 0.0050  | +         |
| CEACAM4 | carcinoembryonic antigen-related cell adhesion molecule 4 | 21516 | 0.0050  | -         |

doi:10.1371/journal.pone.0134654.t002

associations was for the methylation of the gene encoding DNA methyltransferase 1 (DNMT1) which is known to be involved in early phases of development. Thus, the link between methylation alteration and kidney dysfunction may result from a nonspecific imprinting process.
Our analysis reveals mostly a lower methylation profile in cases with 74 sites less methylated and 13 sites more methylated when compared to controls. Although permutation analyses allow calculation of order statistic distributions and multiple-testing adjusted P-values [25], we cannot exclude false positive or negative results due to the small sample size and the low variation in site-specific methylation between individuals [22, 23]. Thus, we acknowledge caution in interpreting the results of differentially methylated genes and the necessity to replicate these findings in other groups of subjects.

Reduced methylation has been reported with aging [29], smoking [30], gender with unmethylated X chromosome in males [31], but also with caloric restriction during pregnancy [32] and with type 2 diabetes [33]. Our data provide for the first time evidence of site-specific fetal-hyperglycemia association for a certain number of CpG sites which are less methylated in case of fetal exposure to hyperglycemia.

The positive correlations observed in the case group between renal function and the average $\beta$-value of the 74 CpG sites down-methylated support a potential role for methylation as an epigenetic phenomenon in the programming of renal dysfunction. In rat models of dietary protein restriction, the angiotensin receptor gene 1b (AT1b) in the adrenal is significantly under-methylated early in offspring life, and in vitro, AT1b gene expression is highly dependent on promoter methylation [34]. Also, fibrogenesis in the kidney is a possible mechanism since epigenetic modifications has been shown to cause fibroblast activation [35]. Humans who were prenatally exposed to famine during the Dutch Hunger Winter in 1944–45 had, 6 decades later, less DNA methylation of the imprinted IGF2 gene compared with their unexposed, same-sex siblings [32]. Thus, renin-angiotensin system, fibrogenesis and IGF2 gene may be targeted by epigenetic modifications participating to fetal programing of renal dysfunction. Unfortunately, in our study, none of the differentially methylated CpGs involved these genes/pathways.

Fig 3. Methylation of the DNA (cytosine-5-)methyltransferase 1 gene. Distribution of the level of methylation ($\beta$-value) of the DNMT1 gene in offspring of diabetic fathers and offspring of diabetic mothers. The boxes limits represent first and third quartile of the distribution, with the median inside. Outer whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the box. $p = 0.0004$ between the 2 groups.

doi:10.1371/journal.pone.0134654.g003
Epigenetic mechanisms such as genomic imprinting may contribute to the programming of health and disease (review in [36]). While most genes are expressed from both parental loci simultaneously, some only expressed from either the maternal or the paternal allele, are called parental imprinting genes. Most imprinted genes act during fetal development, making them a plausible candidate for fetal programming [37]. The gene encoding DNA methyltransferase 1 (DNMT1) was the methylated gene in cases that has been picked up by the automated method of literature interrogation. It is a key enzyme in maintaining methylation patterns during cell division and it plays a crucial role in maintaining methylation marks of the imprinted genes [38] and consequently their expression regulation during development. The deletion of DNMT1 causes disruption of the maintenance imprinting leading to fetal death in rodents [39]. It has been shown that hyper-methylation of the DNMT1 promoter is associated with its decreased expression [40]. Thus, methylation modification of DNMT1 may represent a potential mechanism of fetal programming by hyperglycemia causing abnormal kidney development through parental imprinting. Changes in gene expression by epigenetic process are not restricted to imprinted genes. DNMT1 is highly expressed in the kidney and Bechtel et al. demonstrated that it is involved in kidney fibrosis by hypermethylating RASAL1, encoding an inhibitor of the Ras oncprotein associated with the perpetuation of fibroblast activation [35]. Lastly, it is also possible that DNMT1 affects gene expression by mechanisms independent of DNA methylation, as it has been demonstrated earlier in lung carcinoma [41]. Studying methylation levels of some imprinted gene in new-born (cord blood) from gestational diabetes, El Hajj et al. recently found an under-methylation of the maternally imprinted MEST gene but they did not look at DNMT1 [42].

Whether or not fetal exposure to hyperglycemia (or its associated metabolic abnormalities) impacts tissue DNA methylation is still unanswered. To our knowledge, no data exist regarding kidney development and function. However, the relationships between hyperglycemia and DNA methylation have been studied in other tissues. Using the same Infinium Methylation assay than in our study, Volkmar et al. found 266 CpGs with lower methylation levels and only 10 hyper-methylated CpGs in islets isolated from T2D patients compared with non-diabetic individuals [43]. A subgroup of the differentially methylated genes involved pathways implicated in pancreatic β-cell survival and function. Lastly, El-Osta et al. reported that transient hyperglycemia induced histone modification on the promoter of the inflammatory gene NFκB p65 in mice endothelial cells [44].

We cannot rule out that differences in DNA methylation between cases and controls were related to prematurity rather than fetal exposure to hyperglycemia. However, prematurity was late preterm delivery, occurred in a minority of subjects and was not associated with a low birth weight. In addition other mother environmental factors such as diet, physical exercise, body weight gain, or stress may impact DNA methylation.

In conclusion, this study is the first evidence that kidney dysfunction associated with moderate hyperglycemia (or its related metabolic alterations) during fetal development may be mediated by DNA methylation modifications. Confirmatory results in other groups of subjects are needed as well as investigating the direct biological mechanisms linking DNA methylation status and kidney function.

**Acknowledgments**

The authors express their thanks to the study participants, their parents, and their doctors (Hervé Leblanc and Thierry Gabreau, Lariboisière Hospital, Paris, France; Louise Morbois-Trabut and Camille Deybach, Montsouris Institute, Paris, France). We also thank Gilberto Velho for his help in analyzing the DNA methylation specific PCR results.
Author Contributions
Conceived and designed the experiments: JFG RP LSF SPC MM. Performed the experiments: JFG CAK LSF FT PB FR. Analyzed the data: JFG RP CAK NBM LSF FT SPC JPR SH EL PB BB RR PF ER FR MM. Contributed reagents/materials/analysis tools: JFG RP LSF PB ER FR. Wrote the paper: JFG RP MM. Critical revision of the manuscript: RP CAK LSF FT SPC JPR SH EL PB BB RR PF ER FR MM.

References
1. Kramer MS, Olivier M, McLean FH, Dougherty GE, Willis DM, Usher RH. Determinants of fetal growth and body proportionality. Pediatrics. 1990; 86(1):18–26. PMID: 2359680.
2. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008; 359(1):61–73. doi: 10.1056/NEJMra0708473 PMID: 18596274.
3. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, et al. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009; 94(7):2464–70. PMID: 19417040. doi: 10.1210/jc.2009-0305.
4. Dabelea D, Hanson RL, Pettitt DJ, Imperatore G, Gabir MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000; 49(12):2208–11. PMID: 11118027.
5. Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennett PH, Knowler WC. Congenital susceptibility to NIDDM. Role of intrauterine environment. Diabetes. 1999; 48(11):622–8. PMID: 10535497.
6. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982; 307(11):652–9. PMID: 7050706.
7. Keller G, Zimmer G, Mail G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003; 348(2):101–8. PMID: 12519920.
8. Gomez RA, Sequeira Lopez ML, Fernandez L, Chernavvsky DR, Norwood VF. The maturing kidney: development and susceptibility. Ren Fail. 1999; 21(3–4):283–91. PMID: 10416205.
9. Hoffmann M, Farris AB 3rd, Douglas-Denton R, Hoy WE, Bertram JF. Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney Int. 2003; 63(6):2113–22. PMID: 12753298.
10. Sobngwi E, Boudou P, Mauvais-Jarvis F, Leblanc H, Velho G, Vexiau P, et al. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet. 2003; 361(9372):1861–5. PMID: 12788573.
11. Bernhardt WM, Schmitt R, Rosenberger C, Munchenhagen PM, Grone HJ, Frei U, et al. Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int. 2006; 69(1):114–22. PMID: 16374431.
18. Carev D, Saraga M, Saraga-Babic M. Involvement of FGF and BMP family proteins and VEGF in early human kidney development. Histol Histopathol. 2008; 23(7):853–62. PMID: 18437684.

19. Larger E, Marre M, Corvol P, Gasc JM. Hyperglycemia-induced defects in angiogenesis in the chicken choioallantoic membrane model. Diabetes. 2004; 53(3):752–61. PMID: 14988261.

20. Dressler GR. Epigenetics, development, and the kidney. J Am Soc Nephrol. 2008; 19(11):2060–7. PMID: 18715994. doi: 10.1681/ASN.2008010119

21. Ehrlich M. Expression of various genes is controlled by DNA methylation during mammalian development. J Cell Biochem. 2003; 88(5):899–910. PMID: 12616529.

22. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, et al. Genome-wide DNA methylation profiling using Infinium(R) assay. PMID: Epigenomics. 2009; 1(1):177–200. PMID: 22122642. doi: 10.2217/epi.09.14

23. Chowdhury S, Erickson SW, MacLeod SL, Cleves MA, Hu P, Karim MA, et al. Maternal genome-wide DNA methylation patterns and congenital heart defects. PLoS One. 2011; 6(1):e16506. PMID: 21297937. doi: 10.1371/journal.pone.0016506

24. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003; 100(16):9440–5. doi: 10.1073/pnas.1530509100 PMID: 12883005; PubMed Central PMCID: PMC170937.

25. Bush WS, Moore JH. Chapter 11: Genome-wide association studies. PLoS computational biology. 2012; 8(12):e1002822. doi: 10.1371/journal.pcbi.1002822 PMID: 23300413; PubMed Central PMCID: PMC3531285.

26. Hernando H, Shannon-Lowe C, Islam AB, Al-Shahrour F, Rodriguez-Ubreva J, Rodriguez-Cortez VC, et al. The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion. Genome biology. 2013; 14(1):R3. doi: 10.1186/gb-2013-14-1-r3 PMID: 23320978; PubMed Central PMCID: PMC3663113.

27. Febbo PG, Mulligan MG, Slonina DA, Stegmaier K, Di Vizio D, Martinez PR, et al. Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis. BMC genomics. 2007; 8:461. doi: 10.1186/1471-2164-8-461 PMID: 18088408; PubMed Central PMCID: PMC2244637.

28. Palmer ND, Ng MC, Hicks PJ, Mudgal P, Langefeld CD, Freedman BI, et al. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One. 2014; 9(2):e88273. doi: 10.1371/journal.pone.0088273 PMID: 24551085; PubMed Central PMCID: PMC3923777.

29. Gentilini D, Mari D, Castaldi D, Remondini D, Ogliari G, Ostan R, et al. Role of epigenetics in human aging and longevity: genome-wide DNA methylation profile in centenarians and centenarians' offspring. Age. 2012; 35(5):1961–73. doi: 10.1007/s11357-012-9463-1 PMID: 22923132.

30. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. American journal of respiratory and critical care medicine. 2009; 180(5):462–7. doi: 10.1164/rccm.200901-0135OC PMID: 19498054; PubMed Central PMCID: PMC2742762.

31. Cotton AM, Lam L, Affleck JG, Wilson IM, Penaherrera MS, McFadden DE, et al. Chromosome-wide DNA methylation analysis predicts human tissue-specific X inactivation. Human genetics. 2011; 130(2):187–201. doi: 10.1007/s00439-011-1007-8 PMID: 21597963; PubMed Central PMCID: PMC3132437.

32. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008; 105(44):17046–9. doi: 10.1073/pnas.0806560105 PMID: 18955703; PubMed Central PMCID: PMC2579375.

33. Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet. 2012; 21(2):371–83. doi: 10.1093/hmg/ddr472 PMID: 21994764; PubMed Central PMCID: PMC3276268.

34. Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007; 100(4):520–6. PMID: 17255528.

35. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nature medicine. 2010; 16(5):544–50. doi: 10.1038/nm.2135 PMID: 20418885; PubMed Central PMCID: PMC3106179.

36. Fettita LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab. 2006; 91(10):3718–24. PMID: 16849402.

37. Young LE. Imprinting of genes and the Barker hypothesis. Twin Res. 2001; 4(5):307–17. PMID: 11869481.
38. Song J, Teplova M, Ishibe-Murakami S, Patel DJ. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science. 2012; 335(6069):709–12. PMID: 22323818. doi: 10.1126/science.1214453

39. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992; 69(6):915–26. PMID: 1606615.

40. Verma M, Chattopadhyay BD, Paul BN. Epigenetic regulation of DNMT1 gene in mouse model of asthma disease. Mol Biol Rep. 2013; 40:2357–68. doi: 10.1007/s11033-012-2317-1 PMID: 23196709

41. Milutinovic S, Brown SE, Zhuang Q, Szyf M. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J Biol Chem. 2004; 279(27):27915–27. PMID: 15087453.

42. El Hajj N, Pliushch G, Schneider E, Dittrich M, Muller T, Korenkov M, et al. Metabolic programming of MEST DNA methylation by intrauterine exposure to gestational diabetes mellitus. Diabetes. 2013; 62 (4):1320–8. doi: 10.2337/db12-0289 PMID: 23209187; PubMed Central PMCID: PMC3609586.

43. Volkmar M, Dedeuraerderer S, Cunha DA, Ndlovu MN, Defrance M, Deplus R, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. The EMBO journal. 2012; 31(6):1405–26. doi: 10.1038/emboj.2011.503 PMID: 22293752; PubMed Central PMCID: PMC3321176.

44. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of experimental medicine. 2008; 205(10):2409–17. doi: 10.1084/jem.20081188 PMID: 18809715; PubMed Central PMCID: PMC2556800.